secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001453687-25-000064
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track
--------------------------------------------------------------------------------

- Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
- In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.
- No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.
- Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/0001453687-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/rnac-20250408.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer